Cargando…
Evaluation of the contribution of randomised cancer clinical trials evaluating agents without documented single-agent activity
BACKGROUND: With the development of targeted agents, the approach to combination cancer therapy has evolved to focus on identifying ways in which pathway inhibition by one agent may enhance the activity of other agents. In theory, this implies that under this new paradigm, agents are no longer requi...
Autores principales: | Foster, Jared, Freidlin, Boris, Korn, E L, Smith, Malcolm |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7597487/ https://www.ncbi.nlm.nih.gov/pubmed/33122353 http://dx.doi.org/10.1136/esmoopen-2020-000871 |
Ejemplares similares
-
Evaluation of chemoresponse assays as predictive markers
por: Korn, E L, et al.
Publicado: (2015) -
Response to Comment on: ‘Evaluation of chemoresponse assays as predictive biomarkers'
por: Korn, E L, et al.
Publicado: (2015) -
Platform Trials — Beware the Noncomparable Control Group
por: Dodd, Lori E., et al.
Publicado: (2021) -
Evaluation of Chemotherapeutic Agents
por: Engstrom, W. W.
Publicado: (1949) -
Histopathological Evaluation of Dental Pulp of Primary Teeth Pulpotomized with Formocresol with/without a Capping Agent: A Randomized Clinical Trial
por: Oliadarani, Fatemeh Kadkhodaei, et al.
Publicado: (2018)